Live Markets
Wednesday, July 29, 2026·George Town, KY·29°·Partly Cloudy
Markets Open · NYSE·Newsletter·Masthead·
VOL. XII · NO. 117Established MMXIV · George Town, Grand CaymanAtlantic Edition · $4.50

The Cayman Journal

Finance · Business · Technology · Caribbean & Global Affairs
13F HOLDINGS REPORT

Atlas Venture Life Science Advisors, LLC

Quarter ended Q4 2024 · Filed February 6, 2025 · Accession 0001104659-25-010152

Total Value
$819.7M
Positions
13
Other Managers
0
Confidential Omitted
No
View on SEC.gov

Holdings (13)

#IssuerTicker / CUSIPSharesValue% of Filing
1Kymera Therapeutics, Inc.KYMR4,896,462$197.0M24.03%
2Dyne Therapeutics, Inc.DYN8,019,354$188.9M23.05%
3Disc Medicine, Inc.IRON2,509,456$159.1M19.41%
4Third Harmonic Bio, Inc.88427A10710,402,286$107.0M13.06%
5Day One Biopharmaceuticals, Inc.DAWN6,430,257$81.5M9.94%
6Korro Bio, Inc.KRRO1,137,149$43.3M5.28%
7Vigil Neuroscience, Inc.92673K1085,836,874$9.9M1.21%
8Generation Bio, Co.37148K1008,279,484$8.8M1.07%
9Ikena Oncology, Inc.45175G1085,018,178$8.2M1.00%
10Q32 Bio, Inc.QTTB2,092,106$7.2M0.88%
11Aerovate Therapeutics, Inc.0080641071,799,232$4.8M0.58%
12Tectonic Therapeutics, Inc.TECX78,447$3.6M0.44%
13Spero Therapeutics, Inc.SPRO305,255$314,4130.04%